Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01735201 · ClinicalTrials.gov registry record · Phase 2

AGN-199201 for the Treatment of Erythema With Rosacea

A Phase 2 study of Rosacea and Erythema, sponsored by Allergan.

Completed
Registry status
Phase 2
Development phase
357
Enrollment target
1
Study location

NCT01735201: Completed Phase 2 study of Rosacea and Erythema, sponsored by Allergan.

NCT01735201 is a Phase 2 study of Rosacea and Erythema that has completed, run by Allergan. The registered enrollment target is 357 participants, above the 228-participant average among 23 other Rosacea trials with a reported enrollment target (57% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01735201, a Phase 2 study of Rosacea and Erythema, has completed, sponsored by Allergan.

COMPLETED
Registry status
Phase 2
Development phase
357 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.

Primary Outcome

Percentage of participants with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score were assessed on Day 28 hours 2 to 12. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythe

Conditions Studied

Rosacea Erythema

Interventions

  • DRUG AGN-199201 Vehicle
  • DRUG AGN-199201 Dose A
  • DRUG AGN-199201 Dose B
  • DRUG AGN-199201 Dose C

Study Locations (1)

Texas

  • - Austin

Trial Details

FieldValue
Enrollment Target 357 participants
Start Date 2012-12
Est. Completion 2013-06
Phase Phase 2
Allergan

314 total trials

What the finished NCT01735201 record still lists

NCT01735201 is an interventional study that assigns participants to a tested intervention. The registered 357 participants enrollment target is mid-sized for trials with a published cap, above the 228-participant average among 23 other Rosacea trials with a reported enrollment target (57% higher).

The record links to 2 conditions, with Rosacea appearing as the primary indexed condition, and to 4 interventions - of which AGN-199201 Vehicle is the first listed.

NCT01735201 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT01735201 about?

NCT01735201 is a clinical study titled "AGN-199201 for the Treatment of Erythema With Rosacea". This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.

What is the current status of trial NCT01735201?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 357 participants. The study started on 2012-12. Estimated completion is 2013-06.

What conditions does trial NCT01735201 study?

This clinical trial studies the following conditions: Rosacea, Erythema.

What interventions are being tested in trial NCT01735201?

The interventions under investigation include: AGN-199201 Vehicle (DRUG), AGN-199201 Dose A (DRUG), AGN-199201 Dose B (DRUG), AGN-199201 Dose C (DRUG).

Who is sponsoring clinical trial NCT01735201?

This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01735201 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rosacea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01735201's enrollment target sits among peer trials

357 5th of 23 higher than 19 of 23 other Rosacea trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06062888 · 357 participants · Phase 2

    FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial

  • NCT06109766 · 357 participants · NA

    Delivering Evidence-Based Parenting Services to Families in Child Welfare Using Telehealth

  • NCT06231342 · 357 participants · NA

    Endotracheal Tube (ETT) 180: Stylet-loaded Endotracheal Tube Rotation Before Insertion

  • NCT06533826 · 357 participants · Phase 2

    TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01735201, the US trial registry maintained by the National Library of Medicine. NCT01735201 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.